These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 22127392)

  • 1. Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP).
    Hendriksz CJ; Giugliani R; Harmatz P; Lampe C; Martins AM; Pastores GM; Steiner RD; Leão Teles E; Valayannopoulos V;
    J Inherit Metab Dis; 2013 Mar; 36(2):373-84. PubMed ID: 22127392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enzyme replacement therapy outcomes across the disease spectrum: Findings from the mucopolysaccharidosis VI Clinical Surveillance Program.
    Harmatz PR; Lampe C; Parini R; Sharma R; Teles EL; Johnson J; Sivam D; Sisic Z
    J Inherit Metab Dis; 2019 May; 42(3):519-526. PubMed ID: 30834539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)--10-year follow-up of patients who previously participated in an MPS VI Survey Study.
    Giugliani R; Lampe C; Guffon N; Ketteridge D; Leão-Teles E; Wraith JE; Jones SA; Piscia-Nichols C; Lin P; Quartel A; Harmatz P
    Am J Med Genet A; 2014 Aug; 164A(8):1953-64. PubMed ID: 24764221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzyme replacement therapy initiated in adulthood: Findings from the mucopolysaccharidosis VI Clinical Surveillance Program.
    Lampe C; Harmatz PR; Parini R; Sharma R; Teles EL; Johnson J; Sivam D; Sisic Z
    Mol Genet Metab; 2019 Aug; 127(4):355-360. PubMed ID: 31324526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of galsulfase enzyme replacement therapy on the growth of patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).
    Harmatz P; Hendriksz CJ; Lampe C; McGill JJ; Parini R; Leão-Teles E; Valayannopoulos V; Cole TJ; Matousek R; Graham S; Guffon N; Quartel A;
    Mol Genet Metab; 2017 Sep; 122(1-2):107-112. PubMed ID: 28457718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term impact of early initiation of enzyme replacement therapy in 34 MPS VI patients: A resurvey study.
    Horovitz DDG; Leão EKEA; Ribeiro EM; Martins AM; Barth AL; Neri JICF; Kerstenetzky M; Siqueira ACM; Ribeiro BFR; Kim CA; Santos FC; Franco JFS; Lichtvan LCL; Giuliani LR; Rodrigues MDCS; Bonatti RCF; Teixeira TB; Gonçalves A; Lourenço CM; Pereira ASS; Acosta AX
    Mol Genet Metab; 2021 May; 133(1):94-99. PubMed ID: 33678523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes of patients with mucopolysaccharidosis VI treated with galsulfase enzyme replacement therapy since infancy.
    Garcia P; Phillips D; Johnson J; Martin K; Randolph LM; Rosenfeld H; Harmatz P
    Mol Genet Metab; 2021 May; 133(1):100-108. PubMed ID: 33775523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI.
    Brunelli MJ; Atallah ÁN; da Silva EM
    Cochrane Database Syst Rev; 2016 Mar; 3():CD009806. PubMed ID: 26943923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI.
    Brunelli MJ; Atallah ÁN; da Silva EM
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD009806. PubMed ID: 34533215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis VI: clinical facts and figures.
    Harmatz P
    Turk J Pediatr; 2010; 52(5):443-9. PubMed ID: 21434527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme replacement therapy with galsulfase in 34 children younger than five years of age with MPS VI.
    Horovitz DD; Magalhães TS; Acosta A; Ribeiro EM; Giuliani LR; Palhares DB; Kim CA; de Paula AC; Kerstenestzy M; Pianovski MA; Costa MI; Santos FC; Martins AM; Aranda CS; Correa Neto J; Holanda GB; Cardoso L; da Silva CA; Bonatti RC; Ribeiro BF; Rodrigues Mdo C; Llerena JC
    Mol Genet Metab; 2013 May; 109(1):62-9. PubMed ID: 23535281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase.
    Harmatz P; Ketteridge D; Giugliani R; Guffon N; Teles EL; Miranda MC; Yu ZF; Swiedler SJ; Hopwood JJ;
    Pediatrics; 2005 Jun; 115(6):e681-9. PubMed ID: 15930196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and event-based outcomes of patients with mucopolysaccharidosis VI receiving enzyme replacement therapy in Turkey: a case series.
    İnci A; Okur İ; Tümer L; Biberoğlu G; Öktem M; Ezgü F
    Orphanet J Rare Dis; 2021 Oct; 16(1):438. PubMed ID: 34666789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme®) therapy.
    Braunlin E; Rosenfeld H; Kampmann C; Johnson J; Beck M; Giugliani R; Guffon N; Ketteridge D; Sá Miranda CM; Scarpa M; Schwartz IV; Leão Teles E; Wraith JE; Barrios P; Dias da Silva E; Kurio G; Richardson M; Gildengorin G; Hopwood JJ; Imperiale M; Schatz A; Decker C; Harmatz P;
    J Inherit Metab Dis; 2013 Mar; 36(2):385-94. PubMed ID: 22669363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI.
    Furujo M; Kubo T; Kosuga M; Okuyama T
    Mol Genet Metab; 2011 Dec; 104(4):597-602. PubMed ID: 21930407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abnormal granulation of blood granulocytes in mucopolysaccharidosis VI-a case report.
    Krishnagiri C; Ajanahalli RR; Kashyap S; Anegundi R; Boranaik L
    Ann Diagn Pathol; 2013 Feb; 17(1):137-9. PubMed ID: 22056033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective chart review of urinary glycosaminoglycan excretion and long-term clinical outcomes of enzyme replacement therapy in patients with mucopolysaccharidoses.
    Jones SA; Marsden D; Koutsoukos T; Sniadecki J; Tylee K; Phillippo S; Kakkis E
    Mol Genet Metab; 2020 Aug; 130(4):255-261. PubMed ID: 32563631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Up to five years experience with 11 mucopolysaccharidosis type VI patients.
    Brands MM; Oussoren E; Ruijter GJ; Vollebregt AA; van den Hout HM; Joosten KF; Hop WC; Plug I; van der Ploeg AT
    Mol Genet Metab; 2013 May; 109(1):70-6. PubMed ID: 23523338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical effectiveness of enzyme replacement therapy with galsulfase in mucopolysaccharidosis type VI treatment: Systematic review.
    Gomes DF; Gallo LG; Leite BF; Silva RB; da Silva EN
    J Inherit Metab Dis; 2019 Jan; 42(1):66-76. PubMed ID: 30740728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mucopolysaccharidosis type VI: clinical aspects, diagnosis and treatment with enzyme replacement therapy].
    Politei J; Schenone A; Blanco M; Szlago M
    Arch Argent Pediatr; 2014 Jun; 112(3):258-62. PubMed ID: 24862809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.